Pathos Startup Diligence Report
Proceed only as a high-risk biotech/platform diligence candidate. The upside thesis is that multimodal oncology data and AI can improve asset selection and trial design; the diligence burden is proving the model affects clinical outcomes, partnership economics are durable, and the $1.6B valuation is supported by financing terms and realistic milestone-adjusted runway.
Pathos Startup Diligence Report
Pathos qualifies as an uncovered private unicorn based on CB Insights and a May 2025 Series D announcement. Public evidence supports a large AI-oncology financing, an ambitious PathOS platform, major AstraZeneca/Tempus collaboration and clinical-stage positioning, but the investment case rests on private proof of clinical validity, data rights, burn/runway, pipeline ownership and regulatory progress.
Clinical-stage oncology drug development and large data/model partnerships can consume substantial capital before commercial revenue.
Diligence request: Request cash runway, budget-to-actuals, financing plan, milestone-based burn, and sensitivity analysis.
Pipeline value depends on clinical trial success, regulatory clearance and biomarker/model-driven patient-selection claims that public materials do not validate.
Diligence request: Request IND status, clinical protocols, adverse events, endpoints, timelines, regulatory correspondence and asset-by-asset probability-adjusted plans.
The Tempus/AstraZeneca model collaboration and $200M Tempus fee commitment may create dependency, IP, exclusivity and renewal risk.
Diligence request: Review data licenses, model ownership, exclusivity, termination rights, privacy/security controls and data provenance.
Public evidence does not disclose revenue, gross margin, burn, cash, runway, pricing, approved products or customer concentration.
Diligence request: Request audited financials, cash runway, burn, budget-to-actuals, revenue recognition, partnership revenue and board-approved forecast.
Pathos claims AI improves asset selection and trial design, but public sources do not provide validation metrics, model cards or prospective clinical-outcome proof.
Diligence request: Request validation studies, external benchmarks, model governance, error analysis and prospective trial readouts.
Pathos operates where AI platform vendors, data companies, pharma partners and oncology biotech asset owners compete for assets, data, talent and trial sites.
Diligence request: Benchmark win/loss, asset sourcing, data access, trial performance and partner economics against named competitors.
Highly visible AstraZeneca/Tempus relationships may be strategically important; contract economics and renewal/termination terms are private.
Diligence request: Review master agreements, economics, exclusivity, milestones, IP/data ownership and termination provisions.
The May 2025 CEO appointment is recent relative to a large financing and strategic model buildout.
Diligence request: Request leadership scorecards, retention terms, succession plan, board minutes and management reference checks.
Pathos's public financial record centers on a US$1.60B unicorn-list valuation and US$365M Series D; operating financials, cap table, runway and revenue quality are private.
not publicly verifiable confidence: high
No public audited financial statements, quarterly management accounts, revenue, gross margin, EBITDA, cash runway, burn, backlog or AR detail were found in reviewed public sources.
| metric | public signal | status | diligence request |
|---|---|---|---|
| Financing raised recently | US$365M Series D | verified public announcement | Confirm gross/net proceeds, expenses and use of proceeds. |
| Revenue / gross margin / EBITDA | not disclosed in reviewed sources | not_publicly_verifiable | Provide audited financials, monthly management accounts and revenue by line. |
| Cash runway / burn | not disclosed in reviewed sources | not_publicly_verifiable | Provide cash balance, burn, budget-to-actuals and runway sensitivity. |
partially verified confidence: medium
The public valuation anchor is US$1.60B; the latest disclosed financing is US$365M Series D.
| date | event | amount | valuation or total capital | participants or source | verification status |
|---|---|---|---|---|---|
| 2025-05-01 | CB Insights unicorn-list valuation | Not disclosed in row | US$1.60B | New Enterprise Associates | verified public database |
| 2025-05-15 | US$365M Series D | $365M | Approximately US$1.6B post-money | Company / GlobeNewswire announcement | verified company announcement |
| Current | Current cap table / preferences / debt | not publicly disclosed | not publicly verifiable | company request | not_publicly_verifiable |
Private financing documents are required to validate preferences, dilution, option pool and debt.
not publicly verifiable confidence: high
Public sources identify some investors but not current ownership, option pool, preferences, debt or side letters.
| stakeholder | public position | evidence | diligence caveat |
|---|---|---|---|
| Named unicorn-list investors | New Enterprise Associates | CB Insights unicorn row | Confirm current holdings and rights. |
| Recent-round investors | Series D syndicate not fully itemized in fetched excerpt | Series D announcement | Review purchase agreement and side letters. |
| Employees / option holders / debt providers | not publicly disclosed | No public cap-table detail found | Request cap table, option pool, debt and liquidation preferences. |
Pathos has a clear public product/platform narrative, but public evidence does not establish fully commercialized economics.
partially verified confidence: medium
Pathos publicly describes PathOS, Foundry, Scout, Sprint and clinical/preclinical oncology assets.
| product or program | audience | public features | status |
|---|---|---|---|
| PathOS / Foundry | Internal drug-development teams and partners | Shared AI core and oncology foundation model | company-verified description |
| Scout | Asset-selection workflow | Scans investigational therapies and matches to patient subgroups | company-verified description |
| Sprint | Clinical-development pods | Designs biomarker-driven trials and accelerates Go/No-Go decisions | company-verified description |
| Pipeline assets / PRT811 references | Oncology patients and clinical investigators | Clinical/preclinical oncology-development pipeline | partially_verified |
not publicly verifiable confidence: high
Public sources do not disclose approved-product pricing or commercial revenue.
| offering | pricing public | commercial status | diligence request |
|---|---|---|---|
| PathOS platform / partnership work | No | Partnership economics partly disclosed through Tempus fees but customer pricing not public | Provide contract economics, pricing, revenue-recognition and go-to-market plan. |
| Pipeline therapeutics | No | Clinical/preclinical assets; no approved product revenue found | Provide product revenue, pipeline economics and customer contracts. |
| Revenue / gross margin by product | No | not_publicly_verifiable | Provide financial statements and revenue by product/service. |
Public customer evidence is concentrated in strategic relationships, clinical populations or partner references; customer concentration and revenue durability require private records.
partially verified confidence: medium
The most concrete public demand evidence is partner/collaboration and clinical-population positioning, not customer revenue.
| counterparty or group | relationship or use case | public evidence | verification status |
|---|---|---|---|
| Oncology patients / trial populations | Target beneficiary of precision oncology development | Homepage and pipeline positioning | verified positioning, not revenue |
| Biopharma partners | Model and development collaborations | AstraZeneca and Tempus collaboration announcement | verified relationship announcement |
| Commercial customers / revenue accounts | not publicly disclosed | No customer-revenue table found | not_publicly_verifiable |
verified confidence: medium
AstraZeneca and Tempus are material public strategic relationships.
| partner | nature | public evidence | open questions |
|---|---|---|---|
| AstraZeneca | Strategic collaboration for multimodal oncology foundation model | April 2025 announcement | IP, data rights, economics, exclusivity and deliverables. |
| Tempus AI | Data and model-development collaboration; $200M fees to Tempus | April 2025 announcement | Data license term, privacy obligations, termination and model ownership. |
| NEA | Named unicorn-list investor | CB Insights row | Current ownership and investor rights. |
partially verified confidence: medium
Supplier and infrastructure dependencies cannot be fully assessed from public sources.
| dependency | role | public evidence | concentration risk |
|---|---|---|---|
| Tempus oncology data | De-identified oncology data for foundation model | Strategic agreements release | High until license terms and alternatives are confirmed. |
| AstraZeneca collaboration | Model use and oncology R&D collaboration | Strategic agreements release | Medium; strategic value and rights require review. |
| Cloud/compute/lab vendors | Model training and wetlab validation | Not disclosed | Unknown; request vendor list and spend. |
Pathos competes in a well-funded, technically demanding healthcare market where public differentiation claims require clinical, technical and commercial proof.
partially verified confidence: medium
Public positioning indicates several competitor categories rather than a single direct peer set.
| competitor category | examples | overlap | target differentiator | evidence basis |
|---|---|---|---|---|
| AI drug discovery platforms | Recursion, Exscientia, Insilico-style models | AI-enabled asset selection and development | Oncology-specific multimodal foundation model and Tempus/AZ collaboration | PathOS and collaboration sources |
| Oncology biotech asset developers | Clinical-stage oncology biotech companies | Clinical assets, trial sites, biomarkers | Data/model-driven patient selection | Homepage/pipeline claims |
| Data-rich pharma/diagnostics partners | Large pharma, Tempus-like data platforms | Data, clinical trial design, therapeutics | Independent platform plus partnerships | Strategic collaboration announcement |
| axis | target public position | risk or gap | diligence test |
|---|---|---|---|
| Data scale | >200PB claimed access | Data quality/provenance and rights unknown | Review data contracts and validation samples. |
| Clinical execution | Clinical-stage pipeline references | No public efficacy proof by asset | Verify trial status, data and regulatory correspondence. |
| Partner leverage | AstraZeneca/Tempus collaboration | Concentration and IP rights unknown | Review definitive agreements. |
Public GTM evidence is directional; the productivity model and revenue conversion are private.
partially verified confidence: medium
GTM appears partnership- and clinical-pipeline-led.
| channel | public signal | maturity | diligence gap |
|---|---|---|---|
| Strategic biopharma collaborations | AstraZeneca/Tempus model collaboration | announced | Contract economics and renewal terms. |
| Clinical pipeline / trials | Pipeline page and PRT811 references | clinical/preclinical | Asset-specific trial and regulatory data. |
| Commercial product sales | No public pricing or approved product revenue | not_publicly_verifiable | Revenue, pipeline and pricing. |
not publicly verifiable confidence: high
No public quota capacity, pipeline conversion, CAC, payback or bookings productivity was found.
| signal | public evidence | interpretation | missing metric |
|---|---|---|---|
| Funding/news visibility | US$365M Series D | Creates investor and partner attention | Lead conversion / pipeline contribution. |
| Partner or clinical credibility | AstraZeneca/Tempus collaboration | Credibility signal, not a sales productivity metric | Revenue conversion, cycle length, CAC, win/loss. |
| Sales force productivity | not disclosed | Cannot assess GTM efficiency publicly | Quota capacity, pipeline, bookings, CAC and payback. |
R&D is the core value driver; public evidence identifies programs and leaders but not complete validation packages.
partially verified confidence: medium
Public materials disclose selected leaders and role categories, not a complete R&D org, budget or productivity model.
| name or role | public role | background or signal | verification status |
|---|---|---|---|
| Iker Huerga | CEO and board member | Former AstraZeneca Oncology R&D chief data scientist and Tempus Labs EVP per company announcement | verified company announcement |
| AI scientists / AI engineers | Sprint Pod members | Platform page describes AI scientists and engineers alongside clinical/translational leaders | verified role class, named people not public |
| Clinical/translational leaders | Pipeline execution | Implied by clinical-stage pipeline and Sprint Pod description | partially_verified |
partially verified confidence: medium
Pathos has public platform and pipeline references but clinical proof and ownership details remain private.
| program | public status | next milestone or request | risk link |
|---|---|---|---|
| Oncology foundation model | Development with AstraZeneca and Tempus announced | Model validation, governance and deployment rights | R-003 / R-004 |
| PRT811 / PRMT5 references | Phase 1 study/publication references on pipeline page | Current trial status, safety, efficacy and ownership | R-001 |
| Preclinical assets | Multiple preclinical items indicated on pipeline page | Asset list, IP, IND-enabling plans and budget | R-009 |
Public leadership anchors are identifiable, but full headcount, compensation, turnover and employee-relations records are private.
partially verified confidence: medium
Only a partial public org chart can be reconstructed.
| name | role | public background | diligence follow up |
|---|---|---|---|
| Iker Huerga | CEO and board member | Former AstraZeneca Oncology R&D chief data scientist and Tempus Labs EVP per announcement | Reference checks, equity/retention and board mandate. |
| Ryan Fukushima | Advisor and board member after interim CEO role | Mentioned in CEO transition announcement | Clarify ongoing role, governance and continuity. |
| Mohamad Makhzoumi | NEA Co-CEO and Pathos board member | Quoted in strategic agreements release | Confirm board composition and investor governance rights. |
not publicly verifiable confidence: high
Total headcount and hiring trajectory are not public.
| function or region | public signal | status | request |
|---|---|---|---|
| AI / clinical / translational teams | Sprint Pods include AI scientists, engineers and clinical/translational leaders | partially_verified role categories | Provide HRIS headcount by function/location and hiring plan. |
| Executive leadership | CEO transition in May 2025 | verified public leadership anchors | Provide full org chart and retention plan. |
| Total employees / turnover | not disclosed in reviewed sources | not_publicly_verifiable | Provide HRIS, attrition, regretted loss, open roles and compensation bands. |
not publicly verifiable confidence: high
No public turnover, compensation-plan or employee-relations file was available.
| area | public evidence | risk | request |
|---|---|---|---|
| Executive compensation / equity | not disclosed | Retention and incentive alignment unknown | Provide offer letters, equity grants, bonus plans and severance/change-control terms. |
| Employee turnover | not disclosed | Execution and knowledge-retention risk unknown | Provide turnover by function, regretted loss and hiring funnel. |
| Employee relations / claims | not disclosed | Potential disputes or cultural issues not visible | Counsel/HR review of claims, settlements and complaints. |
Public sources do not provide a counsel-grade legal, IP, regulatory, insurance or contract record.
inconclusive confidence: low
No complete litigation docket was produced by public-source review.
| matter type | public evidence | status | diligence request |
|---|---|---|---|
| Clinical/regulatory correspondence | Clinical-stage pipeline public references; no regulator correspondence reviewed | not_publicly_verifiable | Request IND/CTA filings, FDA/EMA correspondence and trial registry reconciliation. |
| Privacy/data rights | >200PB data-access and Tempus de-identified oncology data statements | requires contract/privacy review | Review HIPAA/GDPR/privacy, de-identification, consent and data-use rights. |
| Litigation/regulatory actions | No complete docket review in public-source scope | inconclusive | Run counsel docket and agency searches. |
not publicly verifiable confidence: high
IP and license ownership cannot be confirmed from public sources alone.
| asset or right | public evidence | status | request |
|---|---|---|---|
| Oncology foundation model | Built with AstraZeneca/Tempus, shared among parties on completion per announcement | partially_verified relationship; ownership unclear | Review IP ownership, model weights, derivative works and use restrictions. |
| Tempus data license | Pathos will use Tempus de-identified oncology data | announced, terms private | Review license scope, term, renewals, security, consent and audit rights. |
| Therapeutic asset IP / patents | Pipeline references; no complete patent assignment review | not_publicly_verifiable | Request patent schedule, licenses, chain of title and FTO opinions. |
not publicly verifiable confidence: high
Insurance policies and material contracts are not public.
| document area | why needed | public status | priority |
|---|---|---|---|
| AstraZeneca/Tempus definitive agreements | Determine rights, obligations, milestones, termination and liabilities | not publicly filed | high |
| Insurance policies | Clinical, cyber/privacy and professional-liability exposure | not publicly disclosed | high |
| Employment, IP assignment and contractor agreements | Confirm ownership, retention and dispute exposure | not publicly disclosed | medium |
partially verified confidence: medium
Clinical, privacy/data and healthcare regulatory exposure cannot be resolved publicly.
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | CB Insights lists Pathos as a private unicorn with an approximately US$1.60B valuation. | verified high | SRC-001 |
| EC-002 | Pathos describes itself as an AI-enabled clinical-stage biotech focused on precision oncology. | verified medium | SRC-002 |
| EC-003 | Pathos claims its PathOS platform includes Foundry, Scout and Sprint and has access to more than 200 petabytes of multimodal oncology data. | partially verified medium | SRC-003SRC-008 |
| EC-004 | Pathos announced a US$365M Series D at an approximately US$1.6B post-money valuation. | verified medium | SRC-005 |
| EC-005 | Pathos announced strategic collaborations with AstraZeneca and Tempus, including $200M in fees to Tempus. | verified medium | SRC-006 |
| EC-006 | Pathos appointed Iker Huerga as CEO in May 2025 with prior AstraZeneca and Tempus roles. | verified medium | SRC-007 |
| EC-007 | Pathos publicly describes a pipeline that includes preclinical programs and PRT811-related clinical-study references. | partially verified medium | SRC-004 |
| EC-008 | Pathos revenue, approved products, pricing, customer concentration, burn and runway are not publicly verifiable from reviewed sources. | not publicly verifiable high | SRC-002SRC-003SRC-004SRC-005 |
| EC-009 | The competitive landscape is crowded across AI-enabled drug discovery, precision oncology data and biotech asset development. | partially verified medium | SRC-002SRC-003SRC-006 |
| EC-010 | Legal, IP, regulatory, employment, data-rights and insurance exposure remain largely non-public. | inconclusive low | SRC-002SRC-003SRC-006 |
| ID | Publisher | Title | Accessed |
|---|---|---|---|
| SRC-001 | CB Insights | CB Insights Complete List Of Unicorn Companies | 2026-05-17 |
| SRC-002 | Pathos AI | Pathos homepage | 2026-05-17 |
| SRC-003 | Pathos AI | Pathos platform page | 2026-05-17 |
| SRC-004 | Pathos AI | Pathos pipeline page | 2026-05-17 |
| SRC-005 | Pathos AI / GlobeNewswire | Pathos AI secures $365 million in Series D financing | 2026-05-17 |
| SRC-006 | Pathos AI | Pathos signs strategic agreements with AstraZeneca and Tempus | 2026-05-17 |
| SRC-007 | Pathos AI / GlobeNewswire | Pathos appoints Iker Huerga as CEO | 2026-05-17 |
| SRC-008 | National Cancer Institute | The Cancer Genome Atlas Program | 2026-05-17 |
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.